Oxigene -
A key Phase II trial showed that a combination of CA4P and Avastin significantly improved progression-free survival in ovarian cancer patients compared to Avastin alone.
On June 20, 2016, OXiGENE officially became Mateon Therapeutics (formerly NASDAQ: OXGN, now MATN). Oxigene
Investigated as a topical or systemic treatment to prevent abnormal blood vessel leakage in the eye. A key Phase II trial showed that a
Unlike traditional anti-angiogenic drugs that prevent new vessel formation, OXiGENE’s VDAs targeted existing immature blood vessels within tumors. These agents compromise the tumor's core vasculature, leading to extensive necrosis (cell death) within the center of the tumor. Oxigene